Vasopressin aggravates cardiopulmonary bypass-induced gastric mucosal ischemia

Hagen Bomberg1, Benjamin Bierbach, Stephan Flache

  • 1Department of Thoracic and Cardiovascular Surgery, University Hospital of Saarland, Homburg/Saar, Germany.

Insights

Vasopressin worsens gastric microvascular perfusion during cardiopulmonary bypass (CPB) but prevents endothelin system changes and gastric injury. This suggests vasopressin

Area of Science:

  • Cardiovascular Surgery
  • Gastroenterology
  • Critical Care Medicine

Background:

  • Upper gastrointestinal bleeding (UGIB) is a common complication post-cardiac surgery with cardiopulmonary bypass (CPB).
  • Endothelin system activation and microcirculatory dysfunction are implicated in UGIB pathogenesis.
  • The role of vasopressin in modulating these factors during CPB requires elucidation.

Purpose of the Study:

  • To investigate the impact of vasopressin on gastric mucosal microcirculation during CPB.
  • To determine the involvement of the endothelin system in vasopressin's effects on gastric mucosa.
  • To assess vasopressin's influence on gastric mucosal injury markers.

Main Methods:

  • Pigs underwent 1-hour CPB, with one group receiving vasopressin to maintain arterial pressure.
  • Gastric mucosal blood flow, oxygen saturation, and systemic hemodynamics were continuously monitored.
  • Gastric mucosal endothelin-1 (ET-1) and receptor expressions (ET(A), ET(B)), injury, apoptosis, and leukocytic infiltration were analyzed.

Main Results:

  • CPB impaired gastric microvascular perfusion and increased ET-1 and ET(A) expression.
  • Vasopressin exacerbated CPB-associated malperfusion but fully prevented ET-1 and ET(A) upregulation.
  • Vasopressin did not induce significant gastric mucosal injury, apoptosis, or leukocytic infiltration.

Conclusions:

  • Vasopressin worsens CPB-induced microvascular malperfusion in the gastric mucosa.
  • Despite aggravating malperfusion, vasopressin effectively mitigates endothelin system activation.
  • Vasopressin administration during CPB does not lead to gastric mucosal injury.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
442
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K